Clinical trials: System Sclerosis
Healthy Volunteers
Safety Study of GNbAC1 Monoclonal Antibody in Healthy Male Volunteers
In this clinical study, the safety and tolerability of GNbAC1 as a treatment for MS patients will be evaluated in healthy male volunteers.
- Trial name
- NCT02452996
- Testing
- GNbAC1
- Where
- Germany
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- GeNeuro Innovation SAS
ALS, Amyotrophic Lateral Sclerosis
Cortex Changes in Real/Imagined Movements in Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to track areas of the brain, via functional magnetic resonance imaging (fMRI), that retain structural and functional integrity throughout the lifespan of people with amyotrophic lateral sclerosis…
- Trial name
- NCT00809224
- Where
- United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Multiple Sclerosis
Mindfulness-based Stress Reduction for Multiple Sclerosis
The primary purpose of this study is to assess the feasibility of mindfulness-based stress reduction (MBSR) for adults with any type of multiple sclerosis.
- Trial name
- NCT02340754
- Testing
- Mindfulness-based Stress Reduction, MS Education Control
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- National University of Natural Medicine
Amyotrophic Lateral Sclerosis (ALS), Myasthenia Gravis
Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
This study is evaluating the use of two painless, non-invasive technologies in the assessment of muscle health over time in both healthy volunteers and patients who have diseases that affect the nervous system.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Myasthenia Gravis, Myopathies, Stroke
- Trial name
- QUESST (NCT02118805)
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Multiple Sclerosis
Effectiveness of a Digital Health Application for Multiple Sclerosis (Levidex)
The trial aims to evaluate the effectiveness of a novel digital health application (levidex), which was designed to increase quality of life in persons with multiple sclerosis (MS).
- Trial name
- LAMONT (NCT06090305)
- Testing
- levidex, Control, treatment as usual (TAU)
- Where
- Germany
- Volunteers
- 470 people
- Sponsor
- Gaia AG
Multiple Sclerosis
Early Symptoms in Multiple Sclerosis: an Investigation Using fMRI and Gait Analysis to Develop Personalized Balance Training for People With Low Disability
Background Many people with Multiple Sclerosis (MS) experience a hidden yet clinically significant symptom: impaired balance or a persistent feeling of instability, even during the early stages of the disease (Martin et al.…
- Trial name
- EMS_Rehab (NCT07805733)
- Testing
- Vestibular Physical Therapy
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- LIFE - Research and Care Institute - Santa Lucia IRCCS
Pain, Multiple Sclerosis
A Study to Evaluate the Effects of Cannabis Based Medicine in Patients With Pain of Neurological Origin
To investigate the ability of a cannabis based medicine extract to relieve chronic refractory pain of neurological origin.
- Trial name
- NCT01606176
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 70 people
- Sponsor
- Jazz Pharmaceuticals
Amyotrophic Lateral Sclerosis
Modeling Amyotrophic Lateral Sclerosis With Fibroblasts
Amyotrophic Lateral Sclerosis (ALS) is the most common motor neuron disease in adults. This longitudinal study involves three cohorts of participants: patients with sporadic or hereditary ALS, asymptomatic individuals carrying…
- Trial name
- FIBRALS (NCT06450691)
- Testing
- biopsy
- Where
- France
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Amyotrophic Lateral Sclerosis (ALS)
Personalized Antisense Oligonucleotide Therapy for Participants With TARDBP ALS
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for participants with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in TARDBP.
- Trial name
- NCT07743268
- Testing
- nL-TARDB-006
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- n-Lorem Foundation
Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma
Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex
The purpose of the study is to evaluate the safety and potential side effects of everolimus (an experimental drug) on a person with Tuberous Sclerosis Complex who also has been diagnosed with a brain tumor (astrocytoma) The…
- Trial name
- NCT00411619
- Testing
- Everolimus
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Cognition Disorders, Multiple Sclerosis
A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis
The purpose of this study is to determine the safety and efficacy of C105 in treating the cognitive deficits that can occur due to multiple sclerosis.
- Trial name
- NCT00529581
- Testing
- C105
- Where
- 30 sites in United States
- Volunteers
- 150 people
- Sponsor
- Cognition Pharmaceuticals, LLC
Multiple Sclerosis, Relapsing-Remitting
A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720
The study will assess the patients' satisfaction of treatment after 12 months treatment with fingolimod It also will assess the tolerability profile of fingolimod in a small population.
- Trial name
- NCT01578330
- Testing
- Fingolimod
- Where
- 11 sites in Turkey (Türkiye)
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Scleroderma
Clinical Study of Divozilimab in Patients With Systemic Scleroderma
The study is a randomized, double-blind, placebo-controlled clinical study of the efficacy and safety of divozilimab in patients with systemic scleroderma.The study will enroll adult patients of both sexes diagnosed with active…
- Trial name
- LIBERIUS (NCT05726630)
- Testing
- Divozilimab
- Where
- 3 sites in Russia
- Volunteers
- 152 people
- Sponsor
- Biocad
Relapsing-Remitting Multiple Sclerosis
Effects of Electromechanical Gait Trainer in Patients With Multiple Sclerosis
Multiple Sclerosis is a very disabling disorder in young adult patients leading to an important limitation in daily life activities and social participation.
- Trial name
- NCT01564511
- Testing
- Gait trainer treatment, Conventional treatment
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Universita di Verona
Multiple Sclerosis
MS-Related Disability Worsening and Thalamic Volume Loss
PENTAGON is an observational, non-interventional, multicenter, prospective cohort study conducted at approximately 20 neurology centers and affiliated radiology centers across Germany.
- Trial name
- PENTAGON (NCT07753928)
- Testing
- Disease-Modifying Therapies (DMTs)
- Where
- 2 sites in Germany
- Volunteers
- 2,400 people
- Sponsor
- Jung Diagnostics GmbH
Relapsing-remitting Multiple Sclerosis
A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
This is a double-blind, randomized, active-controlled, parallel group, Phase 1/3 study to compare efficacy, PK, PD and overall safety of CT-P53 with Ocrevus in patients with Relapsing-remitting Multiple Sclerosis.
- Trial name
- NCT05906992
- Testing
- CT-P53, US-Ocrevus, EU-Ocrevus
- Where
- Poland
- Volunteers
- 512 people
- Sponsor
- Celltrion
Multiple Sclerosis
FMT for MS Patients
This is a placebo-controlled, double-blinded, randomized trial design, whereby all patients are eligible to start an injectable therapy, and then randomized to either placebo or FMT for approximately 1 year.
- Trial name
- MS-FMT (NCT04150549)
- Testing
- Fecal Microbial Transplants
- Volunteers
- 34 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Multiple Sclerosis
Clinical Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Ponesimod in Patients With Relapsing-remitting Multiple Sclerosis
This study is an extension to the study AC-058B201 and will investigate the long-term safety, tolerability and efficacy of ponesimod in patients with relapsing-remitting multiple sclerosis.
- Trial name
- NCT01093326
- Testing
- Ponesimod 10 mg, Ponesimod 20 mg, Ponesimod 40 mg
- Where
- 71 sites in United States, Austria and 18 more
- Volunteers
- 353 people
- Sponsor
- Actelion
Multiple Sclerosis, Relapsing-Remitting
A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis
The purpose of this study is to assess the safety and the preliminary efficacy of a single infusion of stimulated autologous CD4+ T cells in patients with Relapsing-Remitting Multiple Sclerosis.
- Trial name
- SCLEROLYM (NCT02427776)
- Testing
- Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope
- Where
- 3 sites in Belgium
- Volunteers
- 2 people
- Sponsor
- Imcyse SA
Multiple Sclerosis, Primary Progressive, Cognitive Impairment
Improving Cognition in People With Progressive Multiple Sclerosis Using Aerobic Exercise and Cognitive Rehabilitation
Given that up to 70% of people with secondary progressive MS are cognitively impaired, the search for effective treatments is considered a priority by people living with the disease.
- Trial name
- NCT03679468
- Testing
- Cognitive Rehabilitation, Aerobic Exercise
- Where
- Canada
- Volunteers
- 309 people
- Sponsor
- Sunnybrook Health Sciences Centre
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.